Onkure Therapeutics, INC Form 4 insider transactions

Director Isaac Manke acquires stock options in OnKure Therapeutics, signaling potential confidence in the company's future.

Jason A. Leverone, CFO of OnKure Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) following the merger with Reneo Pharmaceuticals, as detailed in a Form 4 filing with the SEC.

Valerie Malyvanh Jansen, a director of OnKure Therapeutics, acquired stock options for 15,300 shares of Class A Common Stock on October 4, 2024.

Dylan Hartley, Chief Scientific Officer of OnKure Therapeutics, acquires stock options.

Michael G. Grey, a director of OnKure Therapeutics, acquired stock options for 15,300 shares on October 4, 2024.

Director R Michael Carruthers reports changes in beneficial ownership of OnKure Therapeutics stock following the merger with Reneo Pharmaceuticals.

Samuel Agresta, Chief Medical Officer of OnKure Therapeutics, reports acquisition of stock options following the merger with Reneo Pharmaceuticals.

Reneo Pharmaceuticals' stockholders have approved the merger with OnKure, along with related proposals including the issuance of shares, amendments to the certificate of incorporation, and equity incentive plans.

Braden Michael Leonard, a director and 10% owner of Reneo Pharmaceuticals, acquired additional shares of the company's common stock through BML Investment Partners, L.P.

Reneo Pharmaceuticals provides supplemental disclosures to its proxy statement/prospectus related to its proposed merger with OnKure, addressing litigation alleging misrepresentations and omissions.

Braden Michael Leonard, a director and 10% owner of Reneo Pharmaceuticals, reported purchasing shares of RPHM on September 17 and 18, 2024.

Director Braden Michael Leonard reports acquiring a substantial number of Reneo Pharmaceuticals shares through multiple transactions, increasing his indirect holdings.

Braden Michael Leonard, a director and 10% owner of Reneo Pharmaceuticals, acquired over 270,000 shares of common stock in two days.

Reneo Pharmaceuticals announced its Q2 2024 financial results, highlighting a merger agreement with OnKure, Inc. and a concurrent PIPE financing.

Braden Michael Leonard, a director and 10% owner of Reneo Pharmaceuticals, acquired over 400,000 shares of common stock through BML Investment Partners, L.P.

Reneo Pharmaceuticals and OnKure, Inc. have announced a definitive merger agreement to create a Nasdaq-listed biopharmaceutical company focused on advancing OnKure's portfolio of precision medicines in oncology.